Bernstein Liebhard LLP is investigating whether the Board of Directors of Micrus Endovascular Corp. (“Micrus” or the “Company”) (NASDAQ: MEND) breached its fiduciary duty to its shareholders in agreeing to sell Micrus to Johnson & Johnson (“J&J”) (NYSE: JNJ).

Under the terms of the agreement, Micrus shareholders will receive $23.40 in cash for each share they own, a small premium compared to the Company’s closing price on Friday, placing the total value of the transaction at approximately $480 million. J&J expects the deal to close in the second half of 2010. The investigation is focused on the potential unfairness of the price to Micrus shareholders and the process by which the Micrus Board of Directors considered and approved the transaction.

If you are interested in discussing your rights as a Micrus shareholder and/or have information relating to the matter, please contact U. Seth Ottensoser at (877) 779-1414 or Ottensoser@bernlieb.com.

Bernstein Liebhard has pursued hundreds of securities, consumer and shareholder rights cases and recovered almost $3 billion for its clients. It has been named to The National Law Journal’s “Plaintiffs’ Hot List” in each of the last seven years.

Bernstein Liebhard LLP10 East 40th StreetNew York, New York 10016(877) 779-1414www.bernlieb.com

ATTORNEY ADVERTISING. © 2010 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Grafico Azioni Micrus Endovascular (MM) (NASDAQ:MEND)
Storico
Da Gen 2025 a Feb 2025 Clicca qui per i Grafici di Micrus Endovascular (MM)
Grafico Azioni Micrus Endovascular (MM) (NASDAQ:MEND)
Storico
Da Feb 2024 a Feb 2025 Clicca qui per i Grafici di Micrus Endovascular (MM)